Physician profile
James Barrett
NPI 1841650868
$2,998.06
in general payments reported to CMS, 2019-2025
21 companies · $917 in 2025
The $917 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $142 · 2021: $317 · 2022: $215 · 2023: $61.27 · 2024: $756 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $489.61 | 2024-2025 | |
| Biotronik INC. | $317.40 | 2021 | |
| Abbott Laboratories | $312.00 | 2019-2023 | Ensite |
| Novartis Pharmaceuticals Corporation | $292.76 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $221.11 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $217.33 | 2019-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $169.59 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.08 | 2024-2025 | Jardiance |
| Cardiovascular Systems INC. | $144.88 | 2019 | |
| Merck Sharp & Dohme LLC | $141.81 | 2024-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $128.66 | 2024 | Xarelto |
| Amgen INC. | $88.32 | 2024-2025 | Repatha, Repatha |
| Novo Nordisk INC | $78.09 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $54.61 | 2024-2025 | Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $47.33 | 2024 | Arcalyst |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $38.42 | 2025 | Shingrix, Arexvy |
| Ge Healthcare | $37.22 | 2023 | |
| Lilly USA, LLC | $28.67 | 2025 | Zepbound |
| Altathera Pharmaceuticals LLC | $15.66 | 2025 | Sotalol Hydrochloride |
| Agepha Pharma Fz LLC | $15.61 | 2024 | Lodoco |
| Ucb, INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.